Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition.
- Conditions
- Malnutrition
- Registration Number
- NCT02812134
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Brief Summary
Fibroblast growth factor 23 (FGF23) is a recently discovered phosphaturic hormone produced by osteocytes. It is involved in phosphate-calcium metabolism (via its phosphaturic action and inhibition of 1,25-OH vitamin D).
There are no published studies on the role of FGF23 in undernourished anorexic adolescents taking oral phosphorus supplements.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Adolescents aged from 11 to 17
- Follow-up or hospitalisation for anorexia
- Overt undernutrition (clinical signs of undernutrition, body mass index and the Waterlow index)
- Social security coverage
Exclusion Criteria
- Known pre-existing renal disorders
- Known constitutional disorders of phosphate-calcium metabolism
- Adult patients, legal guardianship, incarceration
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FGF23 at inclusion and then once a month for 6 months. Change in the FGF23 level (U/ml) with regard to the exogenous phosphorus intake (doses of Phosphoneuros®, expressed in mg/kg/day)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU Amiens
🇫🇷Amiens, France